Exenatide Reduces CVD Risk for Patients With Diabetes
Exenatide use in type 2 diabetes lowers risk of cardiovascular disease events and hospitalization
MONDAY, Jan. 17 (HealthDay News) -- Patients suffering from type 2 diabetes who are treated with exenatide have a reduced risk of cardiovascular disease (CVD) events and hospitalization, according to a study published in the January issue of Diabetes Care.
Jennie H. Best, Ph.D., from Amylin Pharmaceuticals in San Diego, and colleagues analyzed insurance claims data from the IMS LifeLink Program from June 2005 to March 2009. A total of 420,493 patients with type 2 diabetes were treated with exenatide or other glucose-lowering therapies. CVD events and hospitalization of these patients were identified by retrospective database analysis.
The patients with type 2 diabetes were treated with either exenatide (n = 39,275) twice daily or with other glucose lowering drugs (n = 381,218). Patients treated with exenatide were less likely to suffer from a CVD event (hazard ratio [HR], 0.81). Patients taking exenatide had reduced rates of CVD-induced hospitalization (HR, 0.88) and hospitalization due to other causes (HR, 0.94).
"In this retrospective epidemiological study, exenatide-treated patients were 19 percent less likely to have a CVD event than patients treated with other glucose-lowering agents; exenatide-treated patients were also less likely to experience CVD-related and all-cause hospitalization," the authors write.
Several of the study authors disclosed financial ties to Amylin Pharmaceuticals, IMS Health and/or Eli Lilly.